Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.

Sponsor
Hayat Abad Medical Complex, Peshawar
Study ID
NCT07055529
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Vitiligo, Generalized

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • Group A recieving PUVA therapy — DRUG
    This group A will recieve PUVA therapy twice weekly for 6 months
  • Group B receiving Tablet Tofacitinib — DRUG
    This group will be given tablet Tofacitinib 5mg twice daily for 6 months

Study Details

This study aims to compare the efficacy and safety of PUVA versus Tofacitinib in the treatment of generalized vitiligo. Given the high prevalence of vitiligo in Pakistan and the significant psychosocial impact on patients, particularly in Peshawar, this study will provide valuable insights into optimal treatment strategies.

Key Dates

Start date
Jun 1, 2026
Status verified
Jun 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
64 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Other: Group A in which the patient will recieve PUVA therapy
    The Study will have two groups and in this group patients will recieve Psoralen combined with UVA (PUVA) therapy
  • Other: Group B in which the patient will be given Tofacitinib 5mg
    This study will have two groups and this group will recieve tablet tofacitinib 5mg

Primary Outcome Measure

Assesment of repigmentation [ Time Frame: Six Months ]

Central Contacts